CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. announced today that Markus Warmuth, M.D., has been appointed President and Chief Executive Officer (CEO), effective immediately.
“We are thrilled to have Markus lead H3 at this magical moment in time – where promising patient-based drug discovery can be realized within the powerful and novel structure of a biotech company,” said Stuart L. Schreiber, Ph.D., H3 Scientific Founder and Founding Director of Chemical Biology at the Broad Institute of Harvard and MIT.